Charcot-Marie-Tooth Disease Type 1 and Type 2 research hub

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 over 21 days in Ambulatory Adult Patients with Charcot-Marie-Tooth Disease Type 1 and Type 2

This study is testing a new medicine, NMD670, for people with Charcot-Marie-Tooth disease types 1 and 2. It compares the medicine to a dummy pill to see if it helps people walk further and if it's safe over 21 days. Participants will be adults who can walk.